DealBook – Pershing Square Capital Management unveiled a proposed slate of directors on Monday that it hopes to elect to the Allergan board.
Pershing Square, which is working with Valeant Pharmaceuticals on a $53 billion hostile bid for the Botox maker Allergan, is still working to secure enough shareholder support to call a special meeting.
